The national cancer data base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade

Cancer

Volumn 83, Issue 8, 1998, Pages 1664-1678

  Chang, Alfred E ^a   Karnell, Lucy Hynds ^b,c   Menck, Herman R ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

Cutaneous melanoma; Melanoma; National Cancer Data; Outcomes

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DATA BASE; DISEASE COURSE; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SOCIOECONOMICS; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CONJUNCTIVAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; DATABASES; DIAGNOSIS-RELATED GROUPS; EYE NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCOME; LENTIGO; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RECTAL NEOPLASMS; REGISTRIES; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UROLOGIC NEOPLASMS; UVEAL NEOPLASMS;

EID: 0032531854     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G     Document Type: Article

References (23)

1. Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995. Cancer 1998;82: 1197-207.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Rigel DS, Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72(4):367-71.
4. Sahel JA, Skeves RA, Albert DM. Intraocular melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: J.B. Lippincott, 1997:1995-2011.
5. Ross MI, Stern SJ. Mucosal melanomas. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. 3rd edition. Philadelphia: J.B. Lippincott, 1998:195-206.
6. Steele GD, Jessup JM, Winchester DP, Menck HR, Murphy GP, editors. National Cancer Data Base: annual review of patient care, 1995. Atlanta: American Cancer Society, 1995.
7. Jessup JM, Menck HR, Winchester DP, Hundahl SA, Murphy GP. The National Cancer Data Base report on patterns of hospital reporting. Cancer 1996;78:1829-37.
8. Commission on Cancer. Data acquisition manual. Chicago: American College of Surgeons Commission on Cancer, 1990.
9. Beahrs OH, Henson DE, Hutter RVP, Myers MH, editors. Manual for staging of cancer. 3rd edition. Philadelphia: J.B. Lippincott, 1988.
10. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992.
11. ICD-O: International classification of disease for oncology. 2nd edition. Geneva: World Health Organization, 1990.
12. SPSS, Inc. SPSS user's guide. Release 6.1. Chicago: SPSS, Inc., 1992.
13. Urist MM, Karnell LH. The National Cancer Data Base: report on melanoma. Cancer 1994;74:782-8.
14. Sutherland CM, Chmiel JS, Henson DE, Cunningham MP, Peace BB, Winchester DP. Patient characteristics, methods of diagnosis, and treatment of melanoma in the United States. Surg Gynecol Obstet 1992;175:129-34.
15. Kirkwood JM, Strawerman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14:7-17.
16. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1306-44.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
18. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314-9.
19. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami H-O. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761-9.
20. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
21. Balch CM, Karakousis C, Mettlin C, Natarajan N, Donegan WL, Smart CR, et al. Management of cutaneous melanoma in the United States. Surg Gynecol Obstet 1984;158: 311-8.
22. Stadelmann WK, Rapaport DP, Soong S-J, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathological features. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. Philadelphia: J.B. Lippincott, 1998:11-35.
23. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg 1987;122:1380-3.